ArticleOphthalmology and therapy2025

Targeting IL-6 Receptor Signaling with Satralizumab in Thyroid Eye Disease: Design of the Phase 3 SatraGO-1 and SatraGO-2 Trials.

Daniel Ezra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.